These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26219845)

  • 1. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats.
    Park MH; Kim DH; Kim MJ; Lee EK; An HJ; Jeong JW; Kim HR; Kim SJ; Yu BP; Moon HR; Chung HY
    J Gerontol A Biol Sci Med Sci; 2016 Mar; 71(3):300-9. PubMed ID: 26219845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
    Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
    PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARα activation by MHY908 attenuates age-related renal inflammation through modulation of the ROS/Akt/FoxO1 pathway.
    Kim YR; Lee EK; Kim DH; Kim KM; Lee B; An HJ; Park JW; Moon KM; Park MH; Chung KW; Park JY; Kim SJ; Yun HY; Son S; Chun P; Moon HR; Chung HY
    Exp Gerontol; 2017 Jun; 92():87-95. PubMed ID: 28323024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHY2013 Modulates Age-related Inflammation and Insulin Resistance by Suppressing the Akt/FOXO1/IL-1β Axis and MAPK-mediated NF-κB Signaling in Aged Rat Liver.
    Cho MJ; Kim DH; Ha S; Bang E; Jung HJ; Moon HR; Chung HY
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):579-592. PubMed ID: 32902936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo.
    Lee BH; Hsu WH; Chang YY; Kuo HF; Hsu YW; Pan TM
    Free Radic Biol Med; 2012 Dec; 53(11):2008-16. PubMed ID: 23022408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARα Agonist, MHY3200, Alleviates Renal Inflammation during Aging via Regulating ROS/Akt/FoxO1 Signaling.
    Kim MJ; Kim DH; Bang E; Noh SG; Chun P; Yokozawa T; Moon HR; Chung HY
    Molecules; 2021 May; 26(11):. PubMed ID: 34073584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
    Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
    Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model.
    Lee Y; Cho JH; Lee S; Lee W; Chang SC; Chung HY; Moon HR; Lee J
    Brain Res; 2019 Feb; 1704():47-58. PubMed ID: 30273550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
    Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
    Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
    Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
    Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
    Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.